Kevin Kunzmann

David Rapoport, MD, explains his institutions development of emergency ventilators through a common sleep apnea device.

How the island nation has set an efficient model of care access and preparation that has allowed them to best manage COVID-19.

The IL-17A-targeting biologic has now been indicated for pediatric plaque psoriasis—marking its fourth indication for patients with chronic diseases.

A new summary of recent cow's milk allergy guidelines show conlficting consensus on identifying and caring for infantile allergic symptoms.

A discussion with Paul W. Armstrong of the University of Alberta, on the pandemic's effect on common ICU conditions.

Clinical investigator and allergist Jonathan Corren, MD, shares insight on the TSLP inhibitor.

Filip Janku, MD, PhD, discusses new post hoc analyses for the opioid receptor antagonist in advanced-illness patients.

Paul W. Armstrong, MD, joins to discuss the virtual cardiology sessions, as well as his team's new findings for vericiguat in high-risk heart failure.

The Proventil HFA generic approval comes at a time of greater inhaler therapy demand due to the respiratory burdens of the coronavirus.

New phase 3 IMMhance findings show durable, sustained effect of the IL-23 inhibitor on a 12-week dose regimen.

COPD patients with unnoticed OSA are at a greater risk of hospital readmission and even all-cause mortality.

Al Rizzo, MD, of the American Lung Association, discusses some of the biggest challenges and questions raised on lung health during the coronavirus pandemic.

New findings show asthmatic children in a highly-polluted region improved in small airway function when their bedroom air was filtered.

New pivotal phase 3 findings support an upcoming sBLA for the IL4 and IL13-targeting agent.

A Vancouver-based cohort shows association between increased infancy antibiotic use, gut microbiome manipulation, and asthma development by age 5.

A new perspective from federal and institutional experts explains the cause of disease severity and mortality in older, cardiovascular-risk patients.

How do e-cigarettes fit into the cardiovascular health paradigm? What more needs to be learned?

A new perspective from a team of Maryland-based cardiovascular clinicians sheds insight on an often forgotten facet of the inherent COVID-19 risk carried by patients with cardiovascular history: the decline in angiotensin-converting enzyme 2 (ACE2) expression associated with aging, and the response of care most common in such patients.

A new perspective from a team of Maryland-based cardiovascular clinicians sheds insight on an often forgotten facet of the inherent COVID-19 risk carried by patients with cardiovascular history: the decline in angiotensin-converting enzyme 2 (ACE2) expression associated with aging, and the response of care most common in such patients.

New findings show the addition of easily identified circulating proteins can provide a more accurate risk assessment.

How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.

Breaking down the details of the E3 trial, and what more needs to be found in the follow-up.

Patients of both sexes and differing levels of LVEF reported similar reductions in NT-proBNP when treated with the combination therapy, versus lone valsartan.

An interventional cardiologist shares perspective on what the new two-year TAVR findings mean for him and colleagues.

New secondary analsysis from the large-scale heart failure trial shows continued benefit of the SGLT2 inhibitor.

New ACC findings show smokers given nicotine or non-nicotine e-cigarettes better in 12-week cessation than those just given counseling.

Results of a pooled analysis of trials from the ORION program offer further insight into the effects of inclisiran on LDL-C in patients with atherosclerotic cardiovascular disease.

Presented at ACC 20, findings from the VICTORIA trial show the novel therapeutic may reduce risk of severe outcomes among high-risk patients with heart failure with reduced ejection fraction.

New PRONOMOS data shows patients receiving lower limb surgery benefit significant from the oral anticoagulant—without increased risk of bleeding.

New trial data shows symptomatic patients with aortic stenosis reported noninferiority in rehospitalization and deaths with the lesser invasive option compared to surgery.